Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.

Author: , BognerJohannes R, BrinsonCynthia, DiaconescuIulian G, EchevarríaJuan, FourieJan, HannaGeorge J, JoshiSamit R, LalezariJacob P, LatailladeMax, LatiffGulam H, MartinsMarcelo, Mendo UrbinaFernando C, StockDavid A, Sussmann PenaOtto A, ThompsonMelanie, Treviño-PérezSandra

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study presents the results of the primary analysis of AI438011, an ongoing trial investigating the efficacy, safety, and dose-response of BMS-663068 in treatment-experienced, HIV-1-infected patients. BMS-663068 is an oral prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 cells.
Paper Details　
Original Abstract of the Article :
BMS-663068 is an oral prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 cells. AI438011 is an ongoing trial investigating the efficacy, safety, and dose-response of BMS-663068 in treatment-experienced, HIV-1-infected patients. Herein we p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3018(15)00177-0

データ提供：米国国立医学図書館（NLM）

A New Weapon in the Fight Against HIV: BMS-663068

HIV, a virus that attacks the immune system, continues to pose a significant global health challenge. This research examines the potential of a new drug, BMS-663068, as a treatment for HIV-infected individuals. It's like discovering a new weapon in the battle against this formidable foe, one that might help turn the tide against the virus. The researchers conducted a clinical trial to evaluate the efficacy and safety of BMS-663068 in individuals with HIV who had previously been treated with other antiretroviral medications. It's like putting a new drug through rigorous testing, making sure it's safe and effective for those who need it.

A Promising New Treatment for HIV

The study results showed that BMS-663068 was well-tolerated and demonstrated promising efficacy in reducing viral load. This suggests that BMS-663068 could be a valuable addition to the arsenal of antiretroviral medications. It's like finding a new oasis in the desert, one that offers hope and relief to those struggling with HIV.

Navigating the Path to an HIV-Free Future

This research highlights the ongoing efforts to develop new and effective treatments for HIV. It's a reminder that we are constantly searching for new ways to combat this challenging virus and improve the lives of those affected.

Dr.Camel's Conclusion

This study offers a glimmer of hope in the ongoing battle against HIV. The promising results for BMS-663068 suggest that we are moving closer to a world where HIV is no longer a life-limiting illness. It's like finding a new path in the desert, one that leads towards a healthier and brighter future for those living with HIV.

Date :
  1. Date Completed 2016-07-27
  2. Date Revised 2019-04-11
Further Info :

Pubmed ID

26423650

DOI: Digital Object Identifier

10.1016/S2352-3018(15)00177-0

Related Literature

Article Analysis
・Effects of fostemsavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.